Cannabis company Khiron Life Sciences reported 68% Y/Y growth in Q2 revenue, driven by strong results within its Medical Cannabis segment.Q2 revenues totaled C$2.8M, C$825,500...
Khiron Life Sciences (KHRNF): Q2 GAAP EPS of -C$0.03.Revenue of C$2.8M (+67.7% Y/Y)Press ReleaseAdjusted EBITDA losses were C$3.9M, compared to the prior quarter loss of C$4.0M...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Sell | Strong Sell |
| Technical Indicators | Neutral | Neutral | Neutral | Strong Sell | Strong Sell |
| Summary | Sell | Sell | Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 18.82 | 19.26 | 18.46 | -0.48 | -2.49% | 212.01K | Toronto | |||
| 2.38 | 2.38 | 2.38 | 0.000 | 0.00% | 0.00 | Toronto | |||
| 3.86 | 3.86 | 3.85 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 17.81 | 18.06 | 17.80 | -0.80 | -4.30% | 8.10M | Toronto | |||
| 28.18 | 28.35 | 28.08 | +0.10 | +0.36% | 1.84M | Toronto | |||
| 93.00 | 94.89 | 92.38 | -1.80 | -1.90% | 510.47K | Toronto | |||
| 46.57 | 48.21 | 46.51 | -1.18 | -2.47% | 1.68M | Toronto | |||
| 0.98 | 0.00 | 0.00 | -0.03 | -2.97% | 745.16K | TSXV | |||
| 77.21 | 77.31 | 76.15 | +1.02 | +1.34% | 221.82K | Toronto | |||
| 67.30 | 67.95 | 67.23 | -0.25 | -0.37% | 3.14M | Toronto | |||
| 103.34 | 104.45 | 103.25 | -0.98 | -0.94% | 1.18M | Toronto | |||
| 8.60 | 8.91 | 8.59 | -0.38 | -4.23% | 1.22M | Toronto | |||
| 2.11 | 2.18 | 2.10 | -0.060 | -2.76% | 6.51M | Toronto | |||
| 176.26 | 180.37 | 175.99 | -3.25 | -1.81% | 201.97K | Toronto | |||
| 6.31 | 6.39 | 6.24 | +0.01 | +0.16% | 1.06M | Toronto |
Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America, North America, and Europe. It operates through three segments: Medical Cannabis Products, Health Services, and Wellbeing Products. The company focuses on the cultivation, production, distribution, and export of tetrahydrocannabinol and CBD (cannabidiol) medical cannabis. It also operates a network of health centers and satellite clinics under the ILANS and Zerenia brands; develops CBD-based cosmeceutical products under the Kuida brand name; and operates Zerenia clinic in Medellin and Peru. Khiron Life Sciences Corp. is based in Vancouver, Canada.